Clinical and immunological response to sublingual allergen-specific immunotherapy: cumulative dose-response relationship

Abdelwahab, Heba W.; Abd El-Maksoud, Amina; A. Elmoneim, Mohamed; Shaaban, Mona; Abu El-Enin, Mohammed A.; Belal, Fathalla; Abd El-Aziz, Abeer Mohamed

doi:10.21608/ejmm.2024.290825.1250

	Clinical and immunological response to sublingual allergen-specific immunotherapy: cumulative dose-response relationship
Egyptian Journal of Medical Microbiology
Volume 33, Issue 3, July 2024, Page 25-31 PDF (318.45 K)
Document Type: New and original researches in the field of Microbiology.
DOI: 10.21608/ejmm.2024.290825.1250
View on SCiNiTO
Authors
Heba W. Abdelwahab ¹; Amina Abd El-Maksoud¹; Mohamed A. Elmoneim ¹; Mona Shaaban²; Mohammed A. Abu El-Enin³; Fathalla Belal⁴; Abeer Mohamed Abd El-Aziz ²
¹Chest Medicine Department, Mansoura University, Egypt
²Microbiology & Immunology Department, Faculty of Pharmacy, Mansoura University, Egypt
³Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Egypt; Department of Pharmacy, Basrah University, College of Science and Technology, Basra 61004, Iraq
⁴Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Mansoura University, Egypt
Abstract
*Background:* Initial studies on sublingual allergen-specific immunotherapy (SLIT) used low doses, but it soon became clear that cumulative dosages higher than the doses used in subcutaneous immunotherapy (SCIT) were required to guarantee clinical efficacy. Objective: This study aimed to evaluate the cumulative dose-dependent clinical and immunological responses to SLIT. Methodology: Patients with allergic airway diseases were included in the study. Patients underwent a skin prick test (SPT) and then received sublingual allergen-specific immunotherapy. Clinical and immunological response variables were recorded at 0, 3, and 6 months intervals of the SLIT schedule (with progressively increasing doses). Results: The study included 74 patients with allergic airway diseases. Symptom and medication scores significantly decreased from baseline (P <0.0001). Hay-specific IgE levels did not decrease significantly, but mite-specific IgE levels decreased by 146%. Hay-specific IgG4 levels increased by 44. 44% after six months of immunotherapy (P<0.01). Eosinophil cationic protein (ECP) levels decreased significantly in patients who underwent six months of sublingual-swallow immunotherapy. Conclusion: There is a clinical cumulative dose-response relationship after SLIT. However, apart from ECP, the immunological cumulative dose-response relationship varies between the allergens.
Keywords
Sublingual-swallow immunotherapy (SLIT); immunological response; clinical response; dose-response relationship; specific IgG4


Statistics Article View: 300 PDF Download: 120